Unfortunately, the company behind the vaccine has closed the program. It’s been adopted by another company and we cannot go further with this particular vaccine. But we really do want to move further and to find out and classify more specifically what characterizes these patients who did have a response. And we do have lots of tissue and blood to work further on with translational research, which is going to be our next step...
Unfortunately, the company behind the vaccine has closed the program. It’s been adopted by another company and we cannot go further with this particular vaccine. But we really do want to move further and to find out and classify more specifically what characterizes these patients who did have a response. And we do have lots of tissue and blood to work further on with translational research, which is going to be our next step. And we are looking out for other companies who will be willing to work with us to further elaborate if there are a place in this landscape of immunotherapeutic therapy for ovarian cancer, which we know there will be, we just have to find the right patients to do it for. So we will be looking out for collaboration with companies in the future as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.